-
B117137-10gBoc-L-leucinol.
-
-
B117137-25gBoc-L-leucinol.
-
-
B116713-100gProtected lysine especially suited for solid phase peptide synthesis: the 2-CI-Z protection is about 50 times more stable than the Z-group.
-
B116713-10gProtected lysine especially suited for solid phase peptide synthesis: the 2-CI-Z protection is about 50 times more stable than the Z-group.
-
B116713-25gProtected lysine especially suited for solid phase peptide synthesis: the 2-CI-Z protection is about 50 times more stable than the Z-group.
-
B116714-100gNalpha-Boc-Nepsilon-Fmoc-L-lysine is used as a pharmaceutical intermediate.
-
B116714-10gNalpha-Boc-Nepsilon-Fmoc-L-lysine is used as a pharmaceutical intermediate.
-
B116714-1gNalpha-Boc-Nepsilon-Fmoc-L-lysine is used as a pharmaceutical intermediate.
-
B116714-25gNalpha-Boc-Nepsilon-Fmoc-L-lysine is used as a pharmaceutical intermediate.
-
B116714-500gNalpha-Boc-Nepsilon-Fmoc-L-lysine is used as a pharmaceutical intermediate.